AI Article Synopsis
- - The study aimed to assess the effectiveness and safety of a chemotherapy regimen, dose-dense gemcitabine and cisplatin (ddGC), in treating muscle-invasive bladder cancer (MIBC) before surgery.
- - Out of 45 patients treated, 92.7% completed the planned chemotherapy cycles, achieving a pathological complete response in 29.3% and an objective response in 41.5%.
- - The results indicated that ddGC was well-tolerated, with severe adverse effects in only 17.8% of patients, and showed promising 2-year disease-free and overall survival rates of 70.8% and 89.2%, respectively.
Article Abstract
Objective: The objective of this study was to evaluate the efficacy and safety of dose-dense gemcitabine and cisplatin (ddGC) as neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC).
Methods: Patients with locally advanced MIBC (cT2aN0M0-cT4N1M0) who received ddGC between December 2017 and December 2023 were included. Regimens of ddGC with pegfilgrastim were administered every 2 weeks for 4 cycles, followed by radical cystectomy. The pathological complete response (CR) (pT0N0) and objective response (OR) (
Results: A total of 45 patients (cT2N0, 60%; cT3N0, 22%; cT4N0, 9%; and cTanyN1, 9%) were included. Of the 41 who underwent cystectomy, 38 (92.7%) completed all planned cycles, with a median RDI of 0.96 (interquartile range [IQR], 0.89-1.00). Overall, CR and OR were achieved in 12 (29.3%) and 17 (41.5%) patients, respectively, increasing to 32.4% and 45.9%, respectively, in cN0 patients. Severe AEs (grade ≥ 3) were observed in eight patients (17.8%), including four hematological toxicities. At a median follow-up of 31 months, 2-year DFS and OS were 70.8% and 89.2%, respectively.
Conclusion: Neoadjuvant ddGC demonstrated good tolerability, efficacy, and safety, suggesting its potential as a treatment option for MIBC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/iju.15524 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!